DOCSLIB.ORG

Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G. P., 526–527 Acyl-homoserine lactone, 163, 836 Aiptasia pulchella (anemone), 54 M.S. Islam (ed.), Transient Receptor Potential Channels, Advances in Experimental 1033 Medicine and Biology 704, DOI 10.1007/978-94-007-0265-3, C Springer Science+Business Media B.V. 2011 1034 Index Airway cells of non-neuronal origin, TRP Allicin (2-propenyl 2-propene thiosulfinate), channels in, 974 66 airway structural and immune cells, Allium, 66, 67t 975–976 Allosteric coupling, 517, 524, 527f, 528 capsaicin receptor and, 976–978 Allosteric gating in thermoTRP, 481–483 intracellular calcium homeostasis and allosteric MWC model, 481, 482f inflammation, 975 capsaicin gating of TRPV1, 481 TRPA1, 974–975 coupling of electric energy, 483 Airway chemoreceptor, 163 single channel recordings, 483 Airway irritation, 641 voltage gating, 483 Airway SMC, molecular expression and Allosteric gating scheme, 525–527 functional role Allyl isothiocyanate (AITC), 66, 67t, 69, 73, active NSCCs 110, 190t, 485, 766, 792, 852, cell-attached single channel recordings, 972 733 Alpha-amino-3-hydroxy-5-methyl-4- homomeric/heteromeric, 734 isoxazolepropionic acid multiple TRPC molecules (AMPA), 156, 161, 547, 576, guinea-pig airway SMCs, 732 999 human airway SMCs, 732 Al-Shawi laboratory, 29 porcine airway SM tissues, 732 ALS/PD, see Guamanian amyotrophic lateral TRPC3-encoded NSCCs sclerosis and parkinsonian 2+ agonist-induced increase in [Ca ]i, dementia (ALS/PD) 736–737 Alvarez, O., 469–486 expression and activity in asthmatic Alveolar capillary endothelium, 978 airway SMCs, 740–741 Alzheimer, 175, 382, 537–538, 575 mediated Ca2+ influx, 739 Alzheimer’s disease, 175, 382, 537 Na+/Ca2+ exchanger-1 and/or L-type Amantini, C., 947–961 Ca2+ channels, 737–738, 737f Ambudkar, I. S., 435–445, 547, 824 phospholipase C activation, 739 + AMG-517, 653–654 resting [Ca2 ]i lowered, 736 Amgen, 646, 652–653 Vm hyperpolarization, 734 TRPC3/TRPC6 gene silencing, 739 Amide I band, 458 Airway smooth muscle hyperreactivity, Amiloride, 278, 750, 839, 863t, 869–870, 920 797–798 Amino acid (aa), 2, 17, 19, 150, 230, AITC 419t–420t, 537f elicited control response vs. signal, 184, 536, 537f comparison, 110 218, 536 Ajoene, 66, 67t 538–557, 536, 537f Aka Mcoln2, see TRPML2 1292–1325, 536, 537f Akey,J.M.,259–260 2-Aminoethoxydiphenyl borate (2-APB), 56, Akt/PKB, 954–955 88, 89f, 91–93, 190, 420, 477, Alarm/defense mechanism, 197 711t, 735t, 852 Albatrellus confluens (neogri- 2-Aminoethyl diphenylborinate (2-APB), 627 folin/albaconol/grifolin), Amino (N) termini, 2f, 2, 3t, 8–9, 12, 15, 211, 47t, 52–53 316, 392, 415, 440, 463, 547, Albatrellus ovinus (scutigeral), 47t, 52 710, 719, 919, 930, 1011 Albert,A.P.,391–404 2-Aminophenylborate (2-APB), 176 ALG-2 protein, 215 4-Aminopyridine, 733 Alkylation, 96 Aminoquinazolines, 647 Allen, E., 921 Amoroso, S., 586 Allergic asthma, 973, 976 AMPA receptor, 156, 161, 547, 576, 999 Allicin (garlic), 66, 67t, 110, 115, 470, 623, Amplification mechanism, 317, 375 782, 792 AMP–PNP (an ATP analog), 10, 11f, 155 Index 1035 AMTB (TRPM8 blocker), 89f, 97, 193t, 195, 2-APB, see 2-Aminoethoxydiphenyl borate 711t, 716 (2-APB); 2-Aminoethyl Amyloid β-peptide (Aβ), 382, 534, 537 diphenylborinate (2-APB) Analgesia, 197–199, 201, 503, 622, 626, 629, 2-APB action, 91–93, 111f, 176, 177t, 190, 647 191t, 420, 441, 477, 584, 603, Analgesic polypeptide HC1 (APHC1), 48t, 54 627, 675, 711t, 715–716, 735t, Anandamide, 48t, 54–55, 61, 142, 190, 768, 932 191t, 493, 556, 646, 822, 893, APHC1, see Analgesic polypeptide HC1 914–915, 953, 989–990, 992, (APHC1) 997 Apical calcium channels, 934, 958 Anaphylaxis, 976 Apoptosis, 55, 177, 200, 215, 231t, 254, 256, Ancistrodial, 47t, 52 263, 279, 288, 294–295, 327, Ancistrotermes cavithorax (ancistrodial), 47t, 532, 536–537, 575, 579, 585, 52 669, 675, 789, 820, 851, 853, Androgen-dependent (AD), 933, 938–939 929–931, 935–938, 940, 948, Androgen-independent (AI), 200, 931, 933 950–956, 959–960, 977 Apoptotic-induced cell death, 947, 949 Androgen-insensitive neuroendocrine phenotype, 254 Apoptotic-resistant neuroendocrine phenotype, 254, 931 Androgen sensitivity, 199–200 Appaloosa horse phenotype, 140, 142, Andrographis paniculata (bitter herbaceous 1017–1018 plant), 61 AP180 protein, 226 Andrographis paniculata (Chinese herb), 627 Aquaporin, 5f, 6, 28, 282f Angiogenesis, 347–348, 708, 710, 711t, Arachidonic acid (AA), 48t, 58t, 61–62, 767–769, 772, 774t, 791, 63t, 64t, 65, 68t, 71, 72t, 94, 795–796, 891, 930, 948, 960 128, 188, 380, 395, 418, 532, Angiotensin (Ang) II receptor, 160, 179, 278, 578, 617, 627, 674–675, 739, 376, 400, 669, 691–692, 715, 763–764, 771, 774t, 792, 800, 719, 764, 787f, 789, 793f, 1013 816, 819, 822, 824, 835, 890, Anionic lysophosphatidylinositol, 65 893, 915–916, 956, 990 Ankyrine-rich TRP (TRPA), 12, 26, 43, 88, Arachidonic acid metabolites, 48t, 58t, 68t, 71, 289, 323, 326–327, 331, 342, 72t, 94, 617, 627, 774t, 890 363, 364t, 365, 365t, 367t, 416, 2-Arachidonoylglycerol, 61 457, 469, 474–475, 493, 547, Arachidonyl trifluoromethyl ketone 563, 616, 688, 710, 732, 750, (AACOCF3), 94 760, 782, 948, 974, 988, 1011 Araki, I., 861–871 Ankyrin repeat domain (ARD), 12, 14 A7R5 aortic smooth muscle cells, 563 X-ray crystallography, 12 A7r5 cells, see Aortic smooth muscle cells Ankyrin repeats, 8f, 12, 13f, 14, 27, 32, 34, (A7r5 cells) 244, 517, 623, 638f, 639, 1013t, ARD, see Ankyrin repeat domain (ARD) 1013, 1015t Arf6, see GTPase ADP-ribosylation Factor 6 Annexin A1, 11, 177–179, 233, 691, 784, 918 (Arf6) pathway Anterior hypothalamus, 998 Arg701, 643–644 Anti-aging factor, see Kallikrein Aromatase deficient (ArKO) mice, 248 Anti-androgen therapy, 199, 938 ARPE19 cell line, 234 Anti-anxiety drugs, 991 Arrhenius, 473 Antidepressant drugs, 991–994 Arrhenius activation energy, 473 Anti-estrogen-receptor (ER), 959 Arrhythmogenic alteration, 180 Anti-inflammatory assay, 55 Arteriosclerosis, 782 Antioxidant enzymes, 532 Arthritis, 458, 618, 640t Aortic smooth muscle cells (A7r5 cells), 563, Artmann, G., 461, 464 693–694, 783, 797, 800 A7r5 vascular smooth muscle cell, 90 Aortic stenosis, 786 Aryl cinnamides, 649t 1036 Index Asakawa, M., 851 and PC-1 function, signalling pathway, Ashford, M. L., 811 290 Asian spice, see Zanthoxylum piperitum A8V, 261–262 (Szechuan pepper) Axonal growth cones, 576, 579 Asn604, 644 AZD-1386 (AstraZeneca), 652t, 654 Aspirin, 55 Asp964 residue, 381 B Asthma, 688, 691–692, 740–741, 973, BAA, see Bisandrographolide A (BAA) 976–977 Bacterial K+ channel (KcsA), 1, 6, 643 Astrocytes, 936, 952, 955, 957 Baez-Nieto, D., 469–486 A563T, 261–262 Bandell, M., 481 ATG initiation codon, 136 BAPTA-AM, 404 Atomic force microscopy, 14, 17 Barritt, G. J., 667–680 Atomic resolution, 6, 33–34 Basic fibroblast growth factor (bFGF), 557, ATP binding, 10, 12, 13f, 150f, 154–155, 157, 576–577, 988 261 Bates-Withers, C., 173–180 ATP-binding cassette protein (ABC Bax, 938, 960 transporter), 151, 157, 814 Bayliss, A., 798 + ATP-dependent K channel (KATP ), 158, 812 Bayliss effect, 158, 160, 798–799 ATP-evoked calcium signalling, 131 Bayliss, W., 158 ATP +Mg2+, 437 Bayliss, W. M., 694 ATP synthesis, 669 B-cell receptor (BCR), 375–376, 375f Atropine, 549t, 597, 599, 722 B-cell signaling, 375 Automated patch clamp Anno 2010 Bcl-2, 938–939, 950 results, 110–120 BCR, see B-cell receptor (BCR) HEK293-TRPA1 cell testing on QPatch, Beckwith–Wiedemann syndrome, 939 111f Bedouin, 1020–1021 TRPA1, 110–112 Beech, D. J., 114 Benign prostatic hyperplasia (BPH), 201 TRPCs, 112–115 Benzimidazol analogue, 649t TRPMs, 112–115 Berbey, C., 753 TRPVs, 115–118 Bernd Nilius, 463 See also individual entries Beta-cell, 94, 538–539, 558 Autophagic dysfunction, 210 Beta-galactoside-binding lectin Galectin 1 Autophagic vesicle, 235 (GAL1), 934, 958 Autophagocytosis, see Autophagy Bezzerides, V. J., 550 Autophagosome, see Autophagic vesicle bFGF, see Basic fibroblast growth factor Autophagy, 210, 211t, 215, 231t, 234, 367t (bFGF) Autosomal dominant polycystic kidney disease Bhave, G., 498 (ADPKD), 17, 71, 73, 88, Biaryl carboxamides, 647, 649t 289–290, 771, 919 Biliary epithelial cells (cholangiocytes), 298, arterial hypertension, 290 667 cardiac and vascular manifestations, 290, Bindels, R., 240, 279 290f Binshtok, A.
Recommended publications
  • Methyl Salicylate and Menthol | Memorial Sloan Kettering Cancer Center

    Methyl Salicylate and Menthol | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Methyl Salicylate and Menthol This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US AMPlify Relief MM [OTC]; BenGay [OTC]; Calypxo HP [OTC]; Capasil [OTC]; Icy Hot [OTC]; Kwan Loong Pain Relieving [OTC]; Precise [OTC]; Salonpas Arthritis Pain [OTC]; Salonpas Jet Spray [OTC]; Salonpas Massage Foam [OTC]; Salonpas Pain Relief Patch [OTC]; Thera-Gesic Plus [OTC]; Thera-Gesic [OTC] What is this drug used for? It is used to ease muscle and joint aches and pain. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If your skin is damaged or has open wounds. Do not put on damaged skin or open wounds. If you are taking any other NSAID. If you are taking a salicylate drug like aspirin. If you are pregnant, plan to become pregnant, or get pregnant while taking this drug. This drug may cause harm to an unborn baby if taken at 20 weeks or later Methyl Salicylate and Menthol 1/7 in pregnancy. If you are between 20 to 30 weeks of pregnancy, only take this drug if your doctor has told you to. Do not take this drug if you are more than 30 weeks pregnant.
  • Eucalyptol (1,8 Cineole) from Eucalyptus As COVID-19 Mpro Inhibitor

    Eucalyptol (1,8 Cineole) from Eucalyptus As COVID-19 Mpro Inhibitor

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 31 March 2020 doi:10.20944/preprints202003.0455.v1 Eucalyptol (1,8 cineole) from eucalyptus as COVID-19 Mpro inhibitor. However, essential oil a potential inhibitor of further research is necessary to investigate COVID 19 corona virus infection by their potential medicinal use. Molecular docking studies Arun Dev Sharma* and Inderjeet Kaur Keywords: COVID-19, Essential oil, Eucalyptol, Molecular docking PG dept of Biotechnology, Lyallpur Khalsa College Jalandhar *Corresponding author, e mail: [email protected] Graphical abstract Abstract Background: COVID-19, a member of corona virus family is spreading its tentacles across the world due to lack of drugs at present. Associated with its infection are cough, fever and respiratory problems causes more than 15% mortality worldwide. It is caused by a positive, single stranded RNA virus from the enveloped coronaviruse family. However, the main viral proteinase (Mpro/3CLpro) has recently been regarded as a suitable target for drug design against SARS infection due to its vital role in polyproteins processing necessary for coronavirus reproduction. Objectives: The present in silico study was designed to evaluate the effect of Eucalyptol (1,8 cineole), a essential oil component from eucalyptus oil, on Mpro by docking study. Methods: In the present study, molecular docking studies were conducted by using 1- click dock and swiss dock tools. Protein interaction mode was calculated by Protein Interactions Calculator. Results: The calculated parameters such as RMSD, binding energy, and binding site similarity indicated effective binding of eucalyptol to COVID-19 proteinase. Active site prediction further validated the role of active site residues in ligand binding.
  • 1 TRP About Online

    1 TRP About Online

    a TR P to Spain International Workshop on Transient Receptor Potential Channels 12th – 14th September 2012 Valencia, Spain www.trp2012.com SCHEDULE and ABSTRACTS BOOK September 2012 Dear participants, Travelling to faraway places in search of spiritual or cultural enlightenment is a millennium old human activity. In their travels, pilgrims brought with them news, foods, music and traditions from distant lands. This friendly exchange led to the cultural enrichment of visitors and the economic flourishing of places, now iconic, such as Rome, Santiago, Jerusalem, Mecca, Varanasi or Angkor Thom. The dissemination of science and technology also benefited greatly from these travels to remote locations. The new pilgrims of the Transient Receptor Potential (TRP) community are also very fond of travelling. In the past years they have gathered at various locations around the globe: Breckenridge (USA), Eilat (Israel), Stockholm (Sweden) and Leuven (Belgium) come to mind. These meetings, each different and exciting, have been very important for the dissemination of TRP research. We are happy to welcome you in Valencia (Spain) for TRP2012. The response to our call has been extraordinary, surpassing all our expectations. The speakers, the modern bards, readily attended our request to communicate their new results. At last count we were already more than 170 participants, many of them students, and most presenting their recent work in the form of posters or short oral presentations. At least 25 countries are sending TRP ambassadors to Valencia, making this a truly international meeting. We like to thank the staff of the Cátedra Santiago Grisolía, Fundación Ciudad de las Artes y las Ciencias for their dedication and excellence in handling the administrative details of the workshop.
  • Therapeutic Targets for the Treatment of Chronic Cough

    Therapeutic Targets for the Treatment of Chronic Cough

    Therapeutic Targets for the Treatment of Chronic Cough Roe, N., Lundy, F., Litherland, G. J., & McGarvey, L. (2019). Therapeutic Targets for the Treatment of Chronic Cough. Current Otorhinolaryngology Reports. https://doi.org/10.1007/s40136-019-00239-9 Published in: Current Otorhinolaryngology Reports Document Version: Publisher's PDF, also known as Version of record Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal Publisher rights Copyright 2019 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [email protected]. Download date:25. Sep. 2021 Current Otorhinolaryngology Reports https://doi.org/10.1007/s40136-019-00239-9 CHRONIC COUGH (K ALTMAN, SECTION EDITOR) Therapeutic Targets for the Treatment of Chronic Cough N.
  • Poison Prevention Packaging: a Guide for Healthcare Professionals

    Poison Prevention Packaging: a Guide for Healthcare Professionals

    PPooiissoonn PPrreevveennttiioonn PPaacckkaaggiinngg:: AA GGuuiiddee FFoorr HHeeaalltthhccaarree PPrrooffeessssiioonnaallss REVISED 2005 CPSC 384 US. CONSUMER PRODUCT SAFETY COMMISSION, WASHINGTON, D.C. 20207 THIS BROCHURE BROUGHT TO YOU BY: U.S. CONSUMER PRODUCT SAFETY COMMISSION Washington, DC 20207 Web site: www.cpsc.gov Toll-free hotline: 1-800-638-2772 The U.S. Consumer Product Safety Commission (CPSC) is a federal agency that helps keep families and children safe in and around their homes. For more information, call the CPSC’s toll-free hotline at 1-800-638-2772 or visit its website at http://www.cpsc.gov. Poison Prevention Packaging: A Guide For Healthcare Professionals (revised 2005) Preface The U.S. Consumer Product Safety Commission (CPSC) administers the Poison Prevention Packaging Act of 1970 (PPPA), 15 U.S.C. §§ 1471-1476. The PPPA requires special (child-resistant and adult-friendly) packaging of a wide range of hazardous household products including most oral prescription drugs. Healthcare professionals are more directly involved with the regulations dealing with drug products than household chemical products. Over the years that the regulations have been in effect, there have been remarkable declines in reported deaths from ingestions by children of toxic household substances including medications. Despite this reduction in deaths, many children are poisoned or have "near-misses" with medicines and household chemicals each year. Annually, there are about 30 deaths of children under 5 years of age who are unintentionally poisoned. Data from the National Electronic Injury Surveillance System (a CPSC database of emergency room visits) indicate that in 2003, an estimated 78,000 children under 5 years of age were treated for poisonings in hospital emergency rooms in the United States.
  • Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic

    Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic

    ANTICANCER RESEARCH 37 : 161-168 (2017) doi:10.21873/anticanres.11301 Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells I-TSANG CHIANG 1,2,3* , WEI-TING CHEN 4* , CHIH-WEI TSENG 5, YEN-CHUNG CHEN 2,6 , YU-CHENG KUO 7, BI-JHIH CHEN 8, MAO-CHI WENG 9, HWAI-JENG LIN 10,11# and WEI-SHU WANG 2,12,13# Departments of 1Radiation Oncology, 6Pathology, and 13 Medicine, and 2Cancer Medical Care Center, National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.; 3Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; 4Department of Psychiatry, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.; 5Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan, R.O.C.; 7Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; 8Department of Laboratory Medicine, Changhua Christian Hospital, Changhua Christian Medical Foundation, Changhua, Taiwan, R.O.C.; 9Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C.; 10 Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.; 11 Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C.; 12 National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. Abstract. The aim of the present study was to investigate the (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP), antitumor effect and mechanism of action of hyperforin in myeloid cell leukemia 1(MCL1), and cyclin-D1] were hepatocellular carcinoma (HCC) SK-Hep1 cells in vitro.
  • The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+-re- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice lease channel important in LEL function, affects bladder physiology. −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. The lower urinary tract (LUT) is composed of the urinary Here, we investigated this phenomenon further by exploring an un- bladder and urethra—structures that serve the simple, reciprocal conventional role for TRPML1 channels in the regulation of Ca2+-signal- functions of storing and voiding urine (15).
  • The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice release channel important in LEL function, affects bladder −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. physiology. Here, we investigated this phenomenon further by exploring an un- The lower urinary tract (LUT) is composed of the urinary conventional role for TRPML1 channels in the regulation of Ca2+-signal- bladder and urethra—structures that serve the simple, reciprocal ing activity and contractility in bladder and urethral smooth muscle cells functions of storing and voiding urine (15).
  • TRP Channel Transient Receptor Potential Channels

    TRP Channel Transient Receptor Potential Channels

    TRP Channel Transient receptor potential channels TRP Channel (Transient receptor potential channel) is a group of ion channels located mostly on the plasma membrane of numerous human and animal cell types. There are about 28 TRP channels that share some structural similarity to each other. These are grouped into two broad groups: Group 1 includes TRPC ("C" for canonical), TRPV ("V" for vanilloid), TRPM ("M" for melastatin), TRPN, and TRPA. In group 2, there are TRPP ("P" for polycystic) and TRPML ("ML" for mucolipin). Many of these channels mediate a variety of sensations like the sensations of pain, hotness, warmth or coldness, different kinds of tastes, pressure, and vision. TRP channels are relatively non-selectively permeable to cations, including sodium, calcium and magnesium. TRP channels are initially discovered in trp-mutant strain of the fruit fly Drosophila. Later, TRP channels are found in vertebrates where they are ubiquitously expressed in many cell types and tissues. TRP channels are important for human health as mutations in at least four TRP channels underlie disease. www.MedChemExpress.com 1 TRP Channel Inhibitors, Antagonists, Agonists, Activators & Modulators (-)-Menthol (E)-Cardamonin Cat. No.: HY-75161 ((E)-Cardamomin; (E)-Alpinetin chalcone) Cat. No.: HY-N1378 (-)-Menthol is a key component of peppermint oil (E)-Cardamonin ((E)-Cardamomin) is a novel that binds and activates transient receptor antagonist of hTRPA1 cation channel with an IC50 potential melastatin 8 (TRPM8), a of 454 nM. Ca2+-permeable nonselective cation channel, to 2+ increase [Ca ]i. Antitumor activity. Purity: >98.0% Purity: 99.81% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg, 1 g Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg (Z)-Capsaicin 1,4-Cineole (Zucapsaicin; Civamide; cis-Capsaicin) Cat.
  • Screening of Bacterial Quorum Sensing Inhibitors in a Vibrio fischeri Luxr-Based Synthetic Fluorescent E

    Screening of Bacterial Quorum Sensing Inhibitors in a Vibrio fischeri Luxr-Based Synthetic Fluorescent E

    pharmaceuticals Article Screening of Bacterial Quorum Sensing Inhibitors in a Vibrio fischeri LuxR-Based Synthetic Fluorescent E. coli Biosensor Xiaofei Qin 1,2, Celina Vila-Sanjurjo 2,3, Ratna Singh 4, Bodo Philipp 5 and Francisco M. Goycoolea 2,6,* 1 Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, China; [email protected] 2 Laboratory of Nanobiotechnology, Institute of Plant Biology and Biotechnology, University of Münster, Schlossplatz 8, D-48143 Münster, Germany; [email protected] 3 Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Campus Vida, s/n, 15782 Santiago de Compostela, Spain 4 Laboratory of Molecular Phytopathology and Renewable Resources, Institute of Plant Biology and Biotechnology, University of Münster, Schlossplatz 8, D-48143 Münster, Germany; [email protected] 5 Institute of Molecular Microbiology and Biotechnology, University of Münster, Corrensstraße 3, D-48149 Münster, Germany; [email protected] 6 School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK * Correspondence: [email protected]; Tel.: +44-1133-431412 Received: 13 August 2020; Accepted: 18 September 2020; Published: 22 September 2020 Abstract: A library of 23 pure compounds of varying structural and chemical characteristics was screened for their quorum sensing (QS) inhibition activity using a synthetic fluorescent Escherichia coli biosensor that incorporates a modified version of lux regulon of Vibrio fischeri. Four such compounds exhibited QS inhibition activity without compromising bacterial growth, namely, phenazine carboxylic acid (PCA), 2-heptyl-3-hydroxy-4-quinolone (PQS), 1H-2-methyl-4-quinolone (MOQ) and genipin. When applied at 50 µM, these compounds reduced the QS response of the biosensor to 33.7% 2.6%, ± 43.1% 2.7%, 62.2% 6.3% and 43.3% 1.2%, respectively.
  • WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T

    WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US).
  • Supplementary Materials Evodiamine Inhibits Both Stem Cell and Non-Stem

    Supplementary Materials Evodiamine Inhibits Both Stem Cell and Non-Stem

    Supplementary materials Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70 Seung Yeob Hyun, Huong Thuy Le, Hye-Young Min, Honglan Pei, Yijae Lim, Injae Song, Yen T. K. Nguyen, Suckchang Hong, Byung Woo Han, Ho-Young Lee - 1 - Table S1. Short tandem repeat (STR) DNA profiles for human cancer cell lines used in this study. MDA-MB-231 Marker H1299 H460 A549 HCT116 (MDA231) Amelogenin XX XY XY XX XX D8S1179 10, 13 12 13, 14 10, 14, 15 13 D21S11 32.2 30 29 29, 30 30, 33.2 D7S820 10 9, 12 8, 11 11, 12 8 CSF1PO 12 11, 12 10, 12 7, 10 12, 13 D3S1358 17 15, 18 16 12, 16, 17 16 TH01 6, 9.3 9.3 8, 9.3 8, 9 7, 9.3 D13S317 12 13 11 10, 12 13 D16S539 12, 13 9 11, 12 11, 13 12 D2S1338 23, 24 17, 25 24 16 21 D19S433 14 14 13 11, 12 11, 14 vWA 16, 18 17 14 17, 22 15 TPOX 8 8 8, 11 8, 9 8, 9 D18S51 16 13, 15 14, 17 15, 17 11, 16 D5S818 11 9, 10 11 10, 11 12 FGA 20 21, 23 23 18, 23 22, 23 - 2 - Table S2. Antibodies used in this study. Catalogue Target Vendor Clone Dilution ratio Application1) Number 1:1000 (WB) ADI-SPA- 1:50 (IHC) HSP70 Enzo C92F3A-5 WB, IHC, IF, IP 810-F 1:50 (IF) 1 :1000 (IP) ADI-SPA- HSP90 Enzo 9D2 1:1000 WB 840-F 1:1000 (WB) Oct4 Abcam ab19857 WB, IF 1:100 (IF) Nanog Cell Signaling 4903S D73G4 1:1000 WB Sox2 Abcam ab97959 1:1000 WB ADI-SRA- Hop Enzo DS14F5 1:1000 WB 1500-F HIF-1α BD 610958 54/HIF-1α 1:1000 WB pAkt (S473) Cell Signaling 4060S D9E 1:1000 WB Akt Cell Signaling 9272S 1:1000 WB pMEK Cell Signaling 9121S 1:1000 WB (S217/221) MEK Cell Signaling 9122S 1:1000